Scynexis (SCYX) Short term Debt (2013 - 2023)
Scynexis' (SCYX) quarterly Short term Debt came in at $34.6 million in Q1 2023, up 371.47% quarter-over-quarter from $7.3 million in Q3 2018.
Analysis
Scynexis (SCYX) Short term Debt (2013 - 2023) Analysis & Trends
Scynexis (SCYX) has reported Short term Debt for 5 consecutive years, with $34.6 million the latest figure, recorded in Q1 2023.
- For the quarter ending Q1 2023, Short term Debt changed N/A year-over-year to $34.6 million; the trailing twelve-month figure through Mar 2023 stood at $34.6 million (changed N/A YoY), and the FY2017 full-year result was $4.3 million, changed N/A from the prior year.
- Short term Debt improved to $34.6 million in Q1 2023 per SCYX's latest filing, from $7.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $34.6 million in Q1 2023 and bottomed at $34.6 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 34.65 Mn |
| Sep 30, 2018 | 7.35 Mn |
| Jun 30, 2018 | 5.47 Mn |
| Mar 31, 2018 | 3.60 Mn |
| Dec 31, 2017 | 4.35 Mn |
| Sep 30, 2017 | 2.85 Mn |
| Jun 30, 2017 | 1.35 Mn |
| Mar 31, 2014 | 15.00 Mn |
| Dec 31, 2013 | 15.00 Mn |